labetalol has been researched along with Infant, Newborn, Diseases in 8 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Infant, Newborn, Diseases: Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines." | 9.34 | Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020) |
| "Labetalol and methyldopa are the two antihypertensive drugs most frequently used to control blood pressure for hypertensive disorders of pregnancy." | 7.80 | Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2014) |
| "Labetalol is used to treat hypertensive crisis in women with preeclampsia." | 7.69 | Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy. ( Guillet, R; Stevens, TP, 1995) |
| "Hypotension is more common after maternal labetalol exposure, regardless of the dosage and route of administration." | 5.38 | Neonatal side effects of maternal labetalol treatment in severe preeclampsia. ( Heida, KY; Hulzebos, CV; Van Veen, TR; Zeeman, GG, 2012) |
| "This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines." | 5.34 | Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020) |
| "Our findings suggest that neonates born to mothers exposed to β blockers in late pregnancy, including labetalol, are at elevated risk for neonatal hypoglycemia and bradycardia." | 3.83 | Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. ( Bateman, BT; Desai, RJ; Fischer, MA; Hernandez-Diaz, S; Huybrechts, KF; Maeda, A; Mogun, H; Patorno, E; Seely, EW, 2016) |
| "Labetalol and methyldopa are the two antihypertensive drugs most frequently used to control blood pressure for hypertensive disorders of pregnancy." | 3.80 | Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2014) |
| "Labetalol is used to treat hypertensive crisis in women with preeclampsia." | 3.69 | Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy. ( Guillet, R; Stevens, TP, 1995) |
| "Neonatal hypertension is increasingly recognized as dramatic improvements in neonatal intensive care, advancements in our understanding of neonatal physiology, and implementation of new therapies have led to improved survival of premature infants." | 2.61 | Neonatal hypertension: cases, causes, and clinical approach. ( Flynn, JT; Starr, MC, 2019) |
| "Hypotension is more common after maternal labetalol exposure, regardless of the dosage and route of administration." | 1.38 | Neonatal side effects of maternal labetalol treatment in severe preeclampsia. ( Heida, KY; Hulzebos, CV; Van Veen, TR; Zeeman, GG, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dublin, S | 1 |
| Idu, A | 1 |
| Avalos, LA | 1 |
| Cheetham, TC | 1 |
| Easterling, TR | 1 |
| Chen, L | 1 |
| Holt, VL | 1 |
| Nance, N | 1 |
| Bider-Canfield, Z | 1 |
| Neugebauer, RS | 1 |
| Reynolds, K | 1 |
| Badon, SE | 1 |
| Shortreed, SM | 1 |
| Xiang, X | 1 |
| Wang, F | 1 |
| Zhao, N | 1 |
| Zhou, Z | 1 |
| Starr, MC | 1 |
| Flynn, JT | 1 |
| Xie, RH | 1 |
| Guo, Y | 1 |
| Krewski, D | 1 |
| Mattison, D | 1 |
| Walker, MC | 1 |
| Nerenberg, K | 1 |
| Wen, SW | 1 |
| Bateman, BT | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Seely, EW | 1 |
| Mogun, H | 1 |
| Maeda, A | 1 |
| Fischer, MA | 1 |
| Hernandez-Diaz, S | 1 |
| Huybrechts, KF | 1 |
| Heida, KY | 1 |
| Zeeman, GG | 1 |
| Van Veen, TR | 1 |
| Hulzebos, CV | 1 |
| Woods, DL | 1 |
| Malan, AF | 1 |
| Stevens, TP | 1 |
| Guillet, R | 1 |
1 review available for labetalol and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Neonatal hypertension: cases, causes, and clinical approach.
Topics: Administration, Intravenous; Antihypertensive Agents; Birth Weight; Blood Pressure; Blood Pressure D | 2019 |
1 trial available for labetalol and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Blood Pressure; Do | 2020 |
6 other studies available for labetalol and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: A retrospective cohort study.
Topics: Antihypertensive Agents; Birth Weight; Female; Humans; Hypertension, Pregnancy-Induced; Infant; Infa | 2022 |
Association between labetalol use for hypertension in pregnancy and adverse infant outcomes.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; In | 2014 |
Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia.
Topics: Adrenergic beta-Antagonists; Atenolol; Bradycardia; Cohort Studies; Female; Humans; Hypertension; Hy | 2016 |
Neonatal side effects of maternal labetalol treatment in severe preeclampsia.
Topics: Adult; Antihypertensive Agents; Case-Control Studies; Female; Fetal Death; Humans; Infant Mortality; | 2012 |
Side effects of labetalol in newborn infants.
Topics: Ethanolamines; Female; Humans; Hypertension; Infant, Newborn; Infant, Newborn, Diseases; Labetalol; | 1983 |
Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy.
Topics: Adult; Eclampsia; Female; Glucagon; Heart Failure; Humans; Infant, Newborn; Infant, Newborn, Disease | 1995 |